Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15315745rdf:typepubmed:Citationlld:pubmed
pubmed-article:15315745lifeskim:mentionsumls-concept:C0003826lld:lifeskim
pubmed-article:15315745lifeskim:mentionsumls-concept:C1265549lld:lifeskim
pubmed-article:15315745lifeskim:mentionsumls-concept:C0003069lld:lifeskim
pubmed-article:15315745lifeskim:mentionsumls-concept:C1442792lld:lifeskim
pubmed-article:15315745lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:15315745pubmed:issue4lld:pubmed
pubmed-article:15315745pubmed:dateCreated2004-8-18lld:pubmed
pubmed-article:15315745pubmed:abstractTextThis review summarises recent advances in the field of transgenic goats for the purpose of producing recombinant proteins in their milk. Production of transgenic goats via pronuclear microinjection of DNA expression vectors has been the traditional method, but this results in low efficiencies. Somatic cell nuclear transfer has dramatically improved efficiencies in rates of transgenesis. Characterisation of transfected cells in vitro before use in nuclear transfer guarantees that kids born are transgenic and of predetermined gender. Using these platform technologies, several recombinant proteins of commercial interest have been produced, although none of them has yet gained marketing approval. Before these technologies are implemented in goat improvement programmes, efficiencies must be improved, costs reduced, and regulatory approval obtained for the marketing of food products derived from such animals.lld:pubmed
pubmed-article:15315745pubmed:languageenglld:pubmed
pubmed-article:15315745pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15315745pubmed:citationSubsetIMlld:pubmed
pubmed-article:15315745pubmed:statusMEDLINElld:pubmed
pubmed-article:15315745pubmed:issn1031-3613lld:pubmed
pubmed-article:15315745pubmed:authorpubmed-author:WandAAlld:pubmed
pubmed-article:15315745pubmed:authorpubmed-author:KeeferC LCLlld:pubmed
pubmed-article:15315745pubmed:authorpubmed-author:KaratzasC NCNlld:pubmed
pubmed-article:15315745pubmed:authorpubmed-author:BaldassarreHHlld:pubmed
pubmed-article:15315745pubmed:authorpubmed-author:LazarisAAlld:pubmed
pubmed-article:15315745pubmed:issnTypePrintlld:pubmed
pubmed-article:15315745pubmed:volume16lld:pubmed
pubmed-article:15315745pubmed:ownerNLMlld:pubmed
pubmed-article:15315745pubmed:authorsCompleteYlld:pubmed
pubmed-article:15315745pubmed:pagination465-70lld:pubmed
pubmed-article:15315745pubmed:meshHeadingpubmed-meshheading:15315745...lld:pubmed
pubmed-article:15315745pubmed:meshHeadingpubmed-meshheading:15315745...lld:pubmed
pubmed-article:15315745pubmed:meshHeadingpubmed-meshheading:15315745...lld:pubmed
pubmed-article:15315745pubmed:meshHeadingpubmed-meshheading:15315745...lld:pubmed
pubmed-article:15315745pubmed:meshHeadingpubmed-meshheading:15315745...lld:pubmed
pubmed-article:15315745pubmed:year2004lld:pubmed
pubmed-article:15315745pubmed:articleTitleState of the art in the production of transgenic goats.lld:pubmed
pubmed-article:15315745pubmed:affiliationNexia Biotechnologies Inc., Dorion-Vaudreuil, Quebec, Canada. hbaldassarre@nexiabiotech.comlld:pubmed
pubmed-article:15315745pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15315745pubmed:publicationTypeReviewlld:pubmed